Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Transforming A European Mid-Sized Pharma: An Interview With Almirall President Jorge Gallardo

Executive Summary

Spain’s Almirall has taken a step back from the hypercompetitive respiratory market through its deal with AstraZeneca. It was becoming too expensive to compete in primary care against big pharma, says company President Jorge Gallardo. Almirall will use proceeds to chart a future course as a specialty pharma focused on dermatology.

You may also be interested in...



Ipsen’s U.S. Business Could Be Profitable In 2016, A Year Early

A turnaround in Ipsen’s U.S. business is underpinning a transformation at the European mid-sized pharmaceutical company, which is planning to narrow its focus to niche therapeutic areas including gastrointestinal endocrine tumors and antispasticity neurotoxins.

Ipsen’s U.S. Business Could Be Profitable In 2016, A Year Early

A turnaround in Ipsen’s U.S. business is underpinning a transformation at the European mid-sized pharmaceutical company, which is planning to narrow its focus to niche therapeutic areas including gastrointestinal endocrine tumors and antispasticity neurotoxins.

AstraZeneca Capitalizing On Respiratory With Actavis’ Divestiture

The British pharma is acquiring Actavis’ unwanted respiratory portfolio in a deal that will help AstraZeneca meet the $8 billion in revenues it expects to achieve from its respiratory franchise by 2023. For Actavis, it means unloading a handful of drugs that were underperforming and neglected.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

OM005224

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel